Compare · AIKI vs ZONE
AIKI vs ZONE
Side-by-side comparison of AIkido Pharma Inc. (AIKI) and Zone Frontier Inc. (ZONE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIKI and ZONE operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- ZONE carries a market cap of $25.5M.
- ZONE has hit the wire 6 times in the past 4 weeks while AIKI has been quiet.
- AIKI has more recent analyst coverage (1 ratings vs 0 for ZONE).
- Company
- AIkido Pharma Inc.
- Zone Frontier Inc.
- Price
- -
- -
- Market cap
- -
- $25.5M
- 1M return
- -
- -46.76%
- 1Y return
- -
- -86.71%
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- AMEX
- IPO
- 2024
- News (4w)
- 0
- 6
- Recent ratings
- 1
- 0
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.
Zone Frontier Inc.
Zone Frontier Inc. (NYSE AMERICAN: ZONE) is helping to build the critical infrastructure that powers the AI economy. Through a growing pipeline of projects, the Company aims to help meet the increasing demand for compute capacity, power, and digital infrastructure required by the world's leading AI companies.
Latest AIKI
- SEC Form SC 13D filed by AIkido Pharma Inc.
- SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)
- Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)
- Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)
- Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)
- Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)
- AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update
- Hayes Anthony bought $8,012 worth of shares (4,000 units at $2.00) (SEC Form 4)
- Wool Kyle Michael bought $8,122 worth of shares (4,000 units at $2.03) (SEC Form 4)
- Devall Christopher Franklin bought $2,278 worth of shares (1,000 units at $2.28), increasing direct ownership by 5% to 23,033 units (SEC Form 4)
Latest ZONE
- SEC Form 10-Q filed by Zone Frontier Inc.
- SEC Form NT 10-Q filed by Zone Frontier Inc.
- SEC Form SCHEDULE 13G filed by Zone Frontier Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Zone Frontier Inc.
- SEC Form SCHEDULE 13G filed by Zone Frontier Inc.
- SEC Form SCHEDULE 13G filed by Zone Frontier Inc.
- Zone Frontier Inc. Provides Shareholder Update on Minnesota Execution and Debt Financing Progress, Completed Strategic Transformation, Insider Share Purchases and Texas Project
- SEC Form 8-K filed by CleanCore Solutions Inc.
- Amendment: SEC Form 10-K/A filed by CleanCore Solutions Inc.
- Zone Frontier Inc. Announces 1-for-60 Reverse Stock Split